ECKARDT, Jan-Niklas, Sebastian STASIK, Christoph ROELLIG, Andreas PETZOLD, Tim SAUER, Sebastian SCHOLL, Andreas HOCHHAUS, Martina CRYSANDT, Tim H BRUEMMENDORF, Ralph NAUMANN, Bjoern STEFFEN, Volker KUNZMANN, Hermann EINSELE, Markus SCHAICH, Andreas BURCHERT, Andreas NEUBAUER, Kerstin SCHAEFER-ECKART, Christoph SCHLIEMANN, Stefan W KRAUSE, Regina HERBST, Mathias HAENEL, Maher HANOUN, Ulrich KAISER, Martin KAUFMANN, Zdeněk RÁČIL, Jiří MAYER, Uta OELSCHLAEGEL, Wolfgang E BERDEL, Gerhard EHNINGER, Hubert SERVE, Carsten MUELLER-TIDOW, Uwe PLATZBECKER, Claudia D BALDUS, Andreas DAHL, Johannes SCHETELIG, Martin BORNHAEUSER, Jan Moritz MIDDEKE and Christian THIEDE. Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia. Leukemia. London: Nature Publishing Group, 2023, vol. 37, No 12, p. 2395-2403. ISSN 0887-6924. Available from: https://dx.doi.org/10.1038/s41375-023-02061-1.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia
Authors ECKARDT, Jan-Niklas, Sebastian STASIK, Christoph ROELLIG, Andreas PETZOLD, Tim SAUER, Sebastian SCHOLL, Andreas HOCHHAUS, Martina CRYSANDT, Tim H BRUEMMENDORF, Ralph NAUMANN, Bjoern STEFFEN, Volker KUNZMANN, Hermann EINSELE, Markus SCHAICH, Andreas BURCHERT, Andreas NEUBAUER, Kerstin SCHAEFER-ECKART, Christoph SCHLIEMANN, Stefan W KRAUSE, Regina HERBST, Mathias HAENEL, Maher HANOUN, Ulrich KAISER, Martin KAUFMANN, Zdeněk RÁČIL (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution), Uta OELSCHLAEGEL, Wolfgang E BERDEL, Gerhard EHNINGER, Hubert SERVE, Carsten MUELLER-TIDOW, Uwe PLATZBECKER, Claudia D BALDUS, Andreas DAHL, Johannes SCHETELIG, Martin BORNHAEUSER, Jan Moritz MIDDEKE and Christian THIEDE.
Edition Leukemia, London, Nature Publishing Group, 2023, 0887-6924.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 11.400 in 2022
RIV identification code RIV/00216224:14110/23:00132558
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1038/s41375-023-02061-1
UT WoS 001085283400001
Keywords in English Acute myeloid leukaemia; Risk factors
Tags 14110212, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 2/2/2024 13:05.
Abstract
Genetic lesions of IKZF1 are frequent events and well-established markers of adverse risk in acute lymphoblastic leukemia. However, their function in the pathophysiology and impact on patient outcome in acute myeloid leukemia (AML) remains elusive. In a multicenter cohort of 1606 newly diagnosed and intensively treated adult AML patients, we found IKZF1 alterations in 45 cases with a mutational hotspot at N159S. AML with mutated IKZF1 was associated with alterations in RUNX1, GATA2, KRAS, KIT, SF3B1, and ETV6, while alterations of NPM1, TET2, FLT3-ITD, and normal karyotypes were less frequent. The clinical phenotype of IKZF1-mutated AML was dominated by anemia and thrombocytopenia. In both univariable and multivariable analyses adjusting for age, de novo and secondary AML, and ELN2022 risk categories, we found mutated IKZF1 to be an independent marker of adverse risk regarding complete remission rate, event-free, relapse-free, and overall survival. The deleterious effects of mutated IKZF1 also prevailed in patients who underwent allogeneic hematopoietic stem cell transplantation (n = 519) in both univariable and multivariable models. These dismal outcomes are only partially explained by the hotspot mutation N159S. Our findings suggest a role for IKZF1 mutation status in AML risk modeling.
PrintDisplayed: 24/7/2024 11:27